Sutro Biopharma, Inc. (STRO) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
STRO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
STRO Revenue Analysis (2016–2024)
As of February 28, 2026, Sutro Biopharma, Inc. (STRO) generated trailing twelve-month (TTM) revenue of $105.6 million, reflecting strong growth of +13.8% year-over-year. The most recent quarter (Q3 2025) recorded $9.7 million in revenue, down 84.8% sequentially.
Looking at the longer-term picture, STRO's 5-year compound annual growth rate (CAGR) stands at +7.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $153.7 million in 2023.
Revenue diversification analysis shows STRO's business is primarily driven by Research and Development Services (100%). With over half of revenue concentrated in Research and Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), STRO has underperformed the peer group in terms of revenue growth. Compare STRO vs INCY →
Peer Comparison
Compare STRO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| STROCurrent | $106M | +13.8% | +7.7% | -384.3% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $62.0M | -59.6% | $54.8M | 88.4% | $-238,453,000 | -384.3% |
| 2023 | $153.7M | +126.8% | $146.9M | 95.6% | $-89,278,000 | -58.1% |
| 2022 | $67.8M | +9.5% | $59.5M | 87.8% | $-128,943,000 | -190.3% |
| 2021 | $61.9M | +44.8% | $52.1M | 84.2% | $-98,524,000 | -159.2% |
| 2020 | $42.7M | -0.0% | $-34,239,000 | -80.1% | $-71,057,000 | -166.3% |
| 2019 | $42.7M | +11.2% | $42.7M | 100.0% | $-55,468,000 | -129.8% |
| 2018 | $38.4M | -25.7% | $-15,843,000 | -41.2% | $-37,223,000 | -96.9% |
| 2017 | $51.7M | -13.4% | $-156,000 | -0.3% | $-19,272,000 | -37.2% |
| 2016 | $59.7M | - | $16.2M | 27.1% | $1.4M | 2.3% |
See STRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STRO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare STRO vs AGIO
See how STRO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is STRO's revenue growth accelerating or slowing?
STRO maintains +13.8% revenue growth, in line with its 5-year CAGR of +7.7%. TTM revenue stands at $106M. Growth rate remains consistent with historical average.
What is STRO's long-term revenue growth rate?
Sutro Biopharma, Inc.'s 5-year revenue CAGR of +7.7% reflects the sustained expansion pattern. Current YoY growth of +13.8% is near this long-term average.
How is STRO's revenue distributed by segment?
STRO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.